MISSISSAUGA, ON, March 10, 2022 /CNW/ - Covalon Technologies
Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an
advanced medical technologies company, announced today the results
of the matters voted upon at its Fiscal 2021 Annual and Special
Meeting of Shareholders ("AGM") held March
9th, 2022.
Shareholders voted in favour of all items of business and each
item of business was approved by the requisite number of votes. The
matters included the election of the Board of Directors, the
appointment of auditors, and the approval of the Company's amended
and restated stock option plan. The total number of shares
represented, either in person or by proxy, totaled 11,323,626 or
43.672%. The voting results are detailed below.
1) The Election of the Board of
Directors
Name of
Nominee
|
Votes FOR
|
%
|
Votes
WITHHELD
|
%
|
Amir
Boloor
|
11,115,121
|
99.383
|
69,030
|
0.617
|
Joseph
Cordiano
|
10,956,731
|
97.967
|
227,420
|
2.033
|
Samantha
Nutt
|
11,029,201
|
98.615
|
154,950
|
1.385
|
Brian
Pedlar
|
11,143,601
|
99.637
|
40,550
|
0.363
|
Abe
Schwartz
|
10,984,911
|
98.219
|
199,240
|
1.781
|
Ron Smith
|
11,116,121
|
99.392
|
68,030
|
0.608
|
2) The Appointment of the
Auditor
|
Votes FOR
|
%
|
Votes
WITHHELD
|
%
|
PricewaterhouseCoopers, LLP
|
11,190,097
|
98.821
|
133,529
|
1.179
|
3) The Approval of the Company's
2019 Amended and Restated Stock Option Plan
|
Votes FOR
|
%
|
Votes
WITHHELD
|
%
|
Amended and Restated
Stock Option Plan
|
10,811,961
|
96.672
|
372,190
|
3.328
|
Final voting results of all matters voted on at the meeting will
be filed on SEDAR at www.sedar.com and further details of the voted
matters can be found in the Company's management information
circular dated February
4th, 2022.
About Covalon
Covalon Technologies Ltd. is a researcher, developer,
manufacturer, and marketer of patent-protected medical products
that improve patient outcomes and save lives in the areas of
advanced wound care, infection management and surgical procedures.
Covalon leverages its patented medical technology platforms and
expertise in two ways: (i) by developing products that are sold
under Covalon's name; and (ii) by developing and commercializing
medical products for other medical companies under development and
license contracts. The Company is listed on the TSX Venture
Exchange, having the symbol COV and trades on the OTCQX Market
under the symbol CVALF. To learn more about Covalon, visit
our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results, the
impact and timing of COVID-19 on operating activities and market
conditions, and other risks, any of which could cause
results, performance, or achievements to differ materially from the
results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific
to the Company. Investors should consult the Company's ongoing
quarterly filings for additional information on risks and
uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter
any forward-looking statements whether as a result of new
information, further events or otherwise.
Website:
www.covalon.com
Twitter:
@covalon
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-announces-voting-results-from-fiscal-2021-annual-and-special-meeting-of-shareholders-301500070.html
SOURCE Covalon Technologies Ltd.